The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies - PubMed (original) (raw)
The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies
K J Kim et al. Growth Factors. 1992.
Abstract
Angiogenesis plays critical roles in organ development during embryonic and fetal life, wound healing and in a variety of pathological conditions. Vascular endothelial growth factor (VEGF) is a secreted growth factor specific for vascular endothelial cells which induces angiogenesis in vivo. To gain a better understanding of the physiological role of VEGF, we have generated and characterized four murine monoclonal antibodies (mAbs) using the 165 amino acid species of recombinant human VEGF as immunogen. These mAbs (A3.13.1, A4.6.1, B4.3.1 and B2.6.2) belong to IgG1 isotype and have high affinities for VEGF (dissociation constants range from 2.2 x 10(-9) to 4 x 10(-10) M). Two different epitopes were detected with these mAbs. One epitope is recognized by mAbs A3.13.1 and B2.6.2, and the other recognized by mAbs A4.6.1 and B4.3.1. The epitope recognized by mAb A4.6.1 appears to be continuous while mAb B2.6.2 recognizes a discontinuous epitope. MAb A4.6.1 recognized three species of VEGF generated by alternative splicing, VEGF121, VEGF165 and VEGF189 while mAb B2.6.2 binds only VEGF165 and VEGF189. Results using an in vitro bovine adrenal cortex endothelial cell proliferation assay, in in vivo vascular permeability assay and an in vivo embryonic chicken angiogenesis assay showed that mAb A4.6.1 has potent VEGF neutralizing activities. MAb A4.6.1 was shown to block the binding of VEGF to its receptor(s) suggesting the inhibitory mechanism for VEGF activities. These well-defined mAbs should be very powerful tools to understand the structure-function relationship of various domains of VEGF and may have therapeutic potential.
Similar articles
- Expression of biologically active isoforms of the tumor angiogenesis factor VEGF in Escherichia coli.
Siemeister G, Schnurr B, Mohrs K, Schächtele C, Marmé D, Martiny-Baron G. Siemeister G, et al. Biochem Biophys Res Commun. 1996 May 15;222(2):249-55. doi: 10.1006/bbrc.1996.0730. Biochem Biophys Res Commun. 1996. PMID: 8670191 - The in vivo bioactivity of vascular endothelial growth factor/vascular permeability factor is independent of N-linked glycosylation.
Walter DH, Hink U, Asahara T, Van Belle E, Horowitz J, Tsurumi Y, Vandlen R, Heinsohn H, Keyt B, Ferrara N, Symes JF, Isner JM. Walter DH, et al. Lab Invest. 1996 Feb;74(2):546-56. Lab Invest. 1996. PMID: 8780172 - Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE. Brekken RA, et al. Cancer Res. 2000 Sep 15;60(18):5117-24. Cancer Res. 2000. PMID: 11016638 - Lymphatic versus blood vascular endothelial growth factors and receptors in humans.
Partanen TA, Paavonen K. Partanen TA, et al. Microsc Res Tech. 2001 Oct 15;55(2):108-21. doi: 10.1002/jemt.1162. Microsc Res Tech. 2001. PMID: 11596156 Review. - Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis.
Shibuya M, Seetharam L, Ishii Y, Sawano A, Gotoh N, Matsushime H, Yamaguchi S. Shibuya M, et al. Princess Takamatsu Symp. 1994;24:162-70. Princess Takamatsu Symp. 1994. PMID: 8983073 Review.
Cited by
- VEGF-Virus Interactions: Pathogenic Mechanisms and Therapeutic Applications.
Sánchez-Martínez C, Grueso E, Calvo-López T, Martinez-Ortega J, Ruiz A, Almendral JM. Sánchez-Martínez C, et al. Cells. 2024 Nov 4;13(21):1815. doi: 10.3390/cells13211815. Cells. 2024. PMID: 39513922 Free PMC article. Review. - Biology and therapeutic targeting of vascular endothelial growth factor A.
Pérez-Gutiérrez L, Ferrara N. Pérez-Gutiérrez L, et al. Nat Rev Mol Cell Biol. 2023 Nov;24(11):816-834. doi: 10.1038/s41580-023-00631-w. Epub 2023 Jul 25. Nat Rev Mol Cell Biol. 2023. PMID: 37491579 Review. - The cancer angiogenesis co-culture assay: In vitro quantification of the angiogenic potential of tumoroids.
Truelsen SLB, Mousavi N, Wei H, Harvey L, Stausholm R, Spillum E, Hagel G, Qvortrup K, Thastrup O, Harling H, Mellor H, Thastrup J. Truelsen SLB, et al. PLoS One. 2021 Jul 7;16(7):e0253258. doi: 10.1371/journal.pone.0253258. eCollection 2021. PLoS One. 2021. PMID: 34234354 Free PMC article. - Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study.
Qin S, Li J, Bai Y, Shu Y, Li W, Yin X, Cheng Y, Sun G, Deng Y, Zhong H, Li Y, Qian X, Zhang L, Zhang J, Chen K, Kang W; HLX04-mCRC03 Investigators. Qin S, et al. BioDrugs. 2021 Jul;35(4):445-458. doi: 10.1007/s40259-021-00484-9. Epub 2021 May 20. BioDrugs. 2021. PMID: 34014555 Free PMC article. Clinical Trial. - Ras Pathways on Prox1 and Lymphangiogenesis: Insights for Therapeutics.
Bui K, Hong YK. Bui K, et al. Front Cardiovasc Med. 2020 Nov 12;7:597374. doi: 10.3389/fcvm.2020.597374. eCollection 2020. Front Cardiovasc Med. 2020. PMID: 33263009 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials